Compare EPR Properties (EPR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Organon & Co. Common Stock — how do they compare? EPR Properties trades at $54.64 (market cap $4.20B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: EPR Properties is the larger of the two by market cap, and EPR Properties pays the higher dividend (6.79%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 48 Days and Organon & Co. Common Stock for 0 Days on average.
| EPR | OGN | |
|---|---|---|
Market Cap | $4.20B | $3.62B |
Volume | 1,395,044 | 2,892,999 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $13.81 |
52-Week Low | $48.71 | $5.70 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $7.71B | $11.04B |
Dividend Yield | 6.79% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $54.80, down 1.1% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The REIT shows strong profitability with a 91.41% gross margin and 37.66% net income margin, though net income dipped slightly in 2026. Recent news highlights its 6.5% dividend yield and focus on diversification beyond theaters into experiential properties, with Q3 2026 earnings due October 29, 2026.
The outlook is mixed: analyst consensus is a Buy with a $65.50 price target, implying ~20% upside, supported by a high yield and undervalued P/FFO. Risks include exposure to leisure and entertainment tenants, rising interest rates impacting financing costs, and the Q1 2026 earnings miss. Cash flow trends show a net outflow in 2026, warranting monitoring of dividend coverage.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
